Search

Food agencies recommend increasing the consumption of aquatic food to promote healthy living and sustainability, and, particularly, to prevent Western lifestyle-related diseases and secure sustainable food systems. This requires growth in global seafood production, and the utilization of low trophic species (LTS) is suggested. LTS are already considered nutritious and important in Asian and Pacific diets. As the use of LTS is expanding in Western diets, producers and consumers need information on the food safety practices associated with them and their nutritional content. LTS are mainly immobile or slow-moving extractive species or organisms that feed on such, and their nutrient and contaminant content varies by species and location. Species-specific knowledge on nutritional contents and safe consumption limits is often missing, making the monitoring and analysis of contaminants, nutrients, and consumption data crucial to guiding the utilization and consumption of LTS. Using global and regional standards regarding nutrients, food hazards, and labeling, this review highlights the appropriate guidelines and regulations for guiding the utilization of selected novel species and also identifies knowledge gaps. [ABSTRACT FROM AUTHOR]

Hypertension, a major health concern linked to heart disease and premature mortality, has prompted a search for alternative treatments due to side effects of existing medications. Sustainable harvesting of low-trophic marine organisms not only enhances food security but also provides a variety of bioactive molecules, including peptides. Despite comprising only a fraction of active natural compounds, peptides are ideal for drug development due to their size, stability, and resistance to degradation. Our review evaluates the anti-hypertensive properties of peptides and proteins derived from selected marine invertebrate phyla, examining the various methodologies used and their application in pharmaceuticals, supplements, and functional food. A considerable body of research exists on the anti-hypertensive effects of certain marine invertebrates, yet many species remain unexamined. The array of assessments methods, particularly for ACE inhibition, complicates the comparison of results. The dominance of in vitro and animal in vivo studies indicates a need for more clinical research in order to transition peptides into pharmaceuticals. Our findings lay the groundwork for further exploration of these promising marine invertebrates, emphasizing the need to balance scientific discovery and marine conservation for sustainable resource use. [ABSTRACT FROM AUTHOR]